Colorcon Ventures Invests in Vedanta Biosciences, a Clinical-Stage Microbial Therapeutics Company
Vedanta Biosciences is developing a potential new category of oral therapies based on defined bacterial consortia and next-generation manufacturing.
HARLEYSVILLE, PA. February 22nd, 2024 – Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in Vedanta Biosciences, a clinical stage life sciences company that designs and manufactures proprietary, orally-delivered bacterial therapies.
Ali Rajabi-Siahboomi, Vice President and Chief Innovation Officer at Colorcon, said, “Vedanta Biosciences is aligned with Colorcon Ventures’ interest in emerging classes of drugs for oral administration. The company’s unique approach within microbial therapeutics has the potential to offer safer and more efficacious treatments for a number of indications. Vedanta has also revolutionized the manufacturing of defined bacterial consortia at scale, which adds significant value to the sector. We look forward to supporting Vedanta Biosciences as they realize the full potential of their platform technology.”
Bernat Olle, Vedanta Biosciences’ CEO, said, “We are pleased to have Colorcon Ventures support us as we move our programs through clinical development and expand our pipeline. Colorcon’s formulation expertise will augment our ability to provide patients with new and effective therapies.”
Colorcon Ventures joins a prominent list of investors who also participated in Vedanta’s fundraising round, including AXA IM Alts, The AMR Action Fund, Bill & Melinda Gates Foundation, K2 HealthVentures, Pfizer, PureTech Health, Skyviews Life Science, and others.
About Colorcon Ventures
Colorcon Ventures targets investments in transformational solutions for the pharmaceutical and nutraceutical industries across R&D, manufacturing, supply chain, and the delivery of pharmaceutical products and services. Colorcon Ventures is the corporate venture fund of Colorcon Inc., a trusted design and development partner to over 4,500 pharmaceutical companies around the world, providing expertise to fast-track pharmaceutical formulation and manufacturing. For more information, please visit Colorcon Ventures or LinkedIn.
About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s pipeline includes clinical-stage product candidates being evaluated for the prevention of recurrent C. difficile infection and inflammatory bowel diseases and a preclinical candidate for the prevention of Gram-negative infections. In addition, the company supports investigator-sponsored studies in various diseases. These investigational therapies are grounded in our team’s pioneering research – published in leading journals including Science, Nature, Cell, and JAMA – to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens, and induce a range of potent immune responses. Vedanta Biosciences controls a foundational portfolio of more than 80 patents and has built what it believes is the industry-leading platform for development of defined bacterial consortia drugs. This platform includes one of the largest libraries of bacteria derived from the human microbiome, vast datasets from human interventional studies, proprietary capabilities in consortium design, and end-to-end capabilities for CGMP-compliant manufacturing of oral drug candidates spanning cell banking, fermentation, lyophilization, and fill finish.
